Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

6selected

Field	ASPIRIN Haematology · Haematology · Level 2	CLOPIDOGREL Haematology · Haematology · Level 2	TICAGRELOR Haematology · Haematology · Level 2	PRASUGREL Haematology · Haematology · Level 2	ABCIXIMAB Haematology · Haematology · Level 3	TIROFIBAN Haematology · Haematology · Level 3
Mechanism of action	Non-specific Irreversible platelet cyclooxygenase inhibitor (COX-1 and 2) via acetylation of serine residues → ↓formation PG precursors. - Inhibits formation of thromboxane (TXA) → inhibit aggregation - At higher doses prostacyclin (PFI2) synthesis also inhibited → vasoconstriction (but endothelium can regenerate COX)	Prodrug. Hepatic activation to active agent (Thiol derivative, by oxidation and hydrolysis) which is an ADP receptor antagonist - Irreversible inhibition of P2Y12 receptor at platelet surface → Inhibits activation of GPIIb/IIIa → Inhibits platelet activation	Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Irreversibly binds the P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Similar mechanism as tirofiban but monoclonal antibody	Antagonises the GpIIb/IIIa receptor, preventing the binding of fibrinogen and platelet crosslinking and aggregation.
Absorption	- PO. BA. 50%. - 300mg Loading. 100mg maint.	- PO. BA 50% - 600mg loading. 75mg maint.	BA=40%	—	—	—
Protein binding	85% protein binding, pKa 3	95% protein binding,	—	—	—	—
Volume of distribution	Vd 10L	Vd unknown	—	—	—	—
Metabolism	- Converted to salicylic acid in GI mucosa and liver - Hepatic conjugation (saturable)	- Hepatic CYP450 2C19 + Esterases to Inactive metab	Metabolized by CYP3A4	Prodrug- 1 step metabolism Less susceptible to CYP polymorphism and CYP inhibition or induction than Clopidogrel	Platelet function typically returns to normal 24-48 hours after infusion ceases	Limited metabolism in humans.
Excretion	- Renal as salicylate	- Renal and faecal elimination	—	—	Platelet function typically returns to normal 24-48 hours after infusion ceases	Excreted in urine and faeces, mostly unchanged
Half-life	- T1/2b 15~20 mins when first order - Dur: 4-6 hrs. (Effect on platelet aggregation will last life of current cohort of platelets (7-10 days)	- T1/2b 7 hours parent drug (30mins metab) Dur: life of platelet	—	—	—	HL 1.9-2.2 hrs
Adverse Effects Toxicity	Bleeding Bronchospasm, Renal toxicity Reye’s Syndrome, GI ulceration Caution with other anticoagulants	Bleeding TTP Agranulocytosis, Neutropenia Significant drug interactions as requires activation by CYP450	—	—	Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction	Haemorrhage Difficulty reversing agent Dose adjustment in renal impairment
Class Group	Antiplatelet	Antiplatelet	Antiplatelet	Antiplatelet	Antiplatelet	Antiplatelet
Introduction	COX inhibitor	ADP Receptor Antagonist - Thienopyridine	ADP Receptor Antagonist - Thienopyridine	ADP Receptor Antagonist - Thienopyridine Prodrug	GP IIb/IIIA Inhibitor	GP IIb/IIIA Inhibitor
Legacy Cicm Level	Level 1	Level 3	Level 3	Level 3	Level 3	Level 3
Main Action	Platelet inhibition	Platelet inhibition	Platelet inhibition	Platelet inhibition	Platelet inhibition	Platelet inhibition